Covid-19 Rapid Antigen test for the Qualitative detection of SARS-CoV-2 antigen from nasopharyngeal swab Specimen
- UID
- MFG/IVD/2020/000161_9edf710ca8e63800fbafa9e64f4094fb_aec2717363d5a144aeb8b1a143001497
- Device class
- Class C
- Brand name
- EzDx
- License holder
- ADVY CHEMICAL PVT. LTD.
- Approving authority
- Central Drug Standards Control Organization, West Zone
- Product information
- EzDxTM Covid 19 Rapid Antigen Test is a rapid chromatographic immunoassay for the qualitative detection of specific antigens to SARS-CoV-2 present in human nasopharyngeal swab specimen. This test is for administration by healthcare workers and labs only, as an aid to early diagnosis of SARS-CoV-2 infection in patient with clinical symptoms with SARS-CoV-2 infection. It provides only an initial screening test result. The result of this test should not be the sole basis for the diagnosis; confirmatory testing is required.
Covid-19 Rapid Antigen test for the Qualitative detection of SARS-CoV-2 antigen from nasopharyngeal swab Specimen is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID MFG/IVD/2020/000161_9edf710ca8e63800fbafa9e64f4094fb_aec2717363d5a144aeb8b1a143001497. This device is marketed under the brand name EzDx. The license holder is ADVY CHEMICAL PVT. LTD., and it is classified as Device Class Class C. The approving authority is Central Drug Standards Control Organization, West Zone.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.